Key Takeaways from R&D Day 2026: From the Device Renaissance to Enlightenment
Orchestra BioMed Investor Relations Blog | November 2026
News & Events
Nov 19, 2026, 9:29:59 AM / by Orchestra BioMed posted in Corporate
Orchestra BioMed Investor Relations Blog | November 2026
Oct 27, 2026, 11:23:21 AM / by Orchestra BioMed posted in Corporate
Orchestra BioMed Investor Relations Blog | October 2026
Oct 9, 2026, 3:39:05 PM / by Orchestra BioMed posted in Corporate
Oct 8, 2026, 11:59:09 AM / by Orchestra BioMed posted in Clinical
Orchestra BioMed Investor Relations Blog | October 2026
Sep 29, 2026, 9:03:53 AM / by Orchestra BioMed posted in Corporate
Sep 23, 2026, 12:54:55 PM / by Orchestra BioMed posted in Corporate
Orchestra BioMed Investor Relations Blog | September 2026
Sep 10, 2026, 12:15:00 AM / by Orchestra BioMed posted in Corporate
Aug 18, 2026, 9:51:16 AM / by Orchestra BioMed posted in Corporate
Orchestra BioMed Investor Relations Blog | August 2026
Orchestra BioMed recently announced financial results for the second quarter of 2026 and provided a business update across our two pivotal-stage cardiovascular programs. The quarter delivered meaningful clarity on the timeline for primary endpoint results from the BACKBEAT global pivotal trial (“BACKBEAT Trial”) as well as planned regulatory submissions for AVIM Therapy, assuming endpoints are met. We also continued to advance the Virtue SAB in the Treatment of Coronary In-Stent Restenosis Trial (“Virtue Trial”), our investigational device exemption (IDE) randomized pivotal trial evaluating Virtue SAB for the treatment of coronary in-stent restenosis. At the same time, we strengthened our financial foundation to support both programs through their next major milestones.
May 27, 2026, 9:00:01 AM / by Orchestra BioMed posted in Finance
Orchestra BioMed Investor Relations Blog | May 2026
Orchestra BioMed recently announced updates to the target timeline for the BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”). These important updates provide clarity on the plan for pivotal data presentation as well as Medtronic’s FDA marketing application for Atrioventricular Interval Modulation Therapy (“AVIM Therapy”) for the treatment of uncontrolled hypertension despite anti-hypertensive medications in patients who are also indicated for a pacemaker.
May 8, 2026, 11:08:39 AM / by Orchestra BioMed posted in Finance
Orchestra BioMed Investor Relations Blog | May 2026
The receipt of $35 million in strategic capital from Medtronic and Ligand reflects continued partner alignment behind Orchestra BioMed’s pivotal-stage cardiovascular pipeline.
© 2026 Orchestra BioMed Inc. Virtue®, BackBeat CNT™ FreeHold Duo®, FreeHold Trio® and Orchestra BioMed™ are trademarks of Orchestra BioMed.
All other trademarks are trademarks of their respective owners.
SM-0020 Rev 01